StockNote
DP1
Central Pharmaceutical Joint Stock Company 1 (DP1), formerly known as National Pharmaceutical Joint Stock Company, was established in 1956. The Company's main production lines include: Import and export business of finished pharmaceutical products, eastern pharmaceuticals, human prevention and treatment, trading, import and export of cosmetics, import and export of raw materials, pharmaceutical packaging, by-products and medical products and other licensed business activities. The company officially traded on the UPCOM market from June 2018.
DP1 currently has a market capitalization of roughly VND 614 billion, placing it in the small-cap group on the Vietnamese stock market. Its current P/E of 4,9x is 37% below its own 8-year average (7,7x), suggesting the stock is trading cheaper than its historical norm. P/B stands at 1x, 34% below its multi-year average of 1,6x. Return on equity (ROE) is at 21,7%, up from 20,6% the year before. Its debt-to-equity ratio of 0,7x is moderate, reflecting a balanced capital structure. In 2025, revenue grew 5% year-on-year while after-tax profit fell 1%.
This note is generated automatically from the stock's real financial data, for reference only — not investment advice.
Revenue & Profit
Unit: VND billion. Growth (%) vs. previous period.
Market Cap
Unit: VND billion. Year-end values; current year uses latest session.
Debt / Equity
Unit: x. Financial debt over shareholders' equity.
Data aggregated from cafef.vn and VNDirect, for reference only, not investment advice.